Annovis Bio, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Annovis Bio, Inc. (ANVS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $1.58 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-13
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $1.58K, a 93.51% increase from fiscal 2024.
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $817.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $1.58K 10-K · filed 2026-03-13 |
| 2024-12-31 | $817.00 10-K · filed 2026-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |